

SHEFFIELD

12 December 2006

Ms Jackie Smith, Head of Investigation
Fitness to Practice Directorate
General Medical Council
5th Floor, St James's Buildings
79 Oxford Street, Manchester M1 6FQ

Re: Professor Richard Eastell – Fitness to Practice Complaint 2005/3223

Dear Ms Smith

Your letter of 5/12/06 is puzzling. It purports to be a reply to my letter of 22/11/06 to Professor Catto about the plausibility of the GMC as recipient of concerns, but is tangential. I have thus returned my letter to Professor Catto retaining the original date.

I am however impressed with your graphic description of the GMC's "sifting". To assist, I attach two letters Professor Eastell himself sent to the GMC showing how he attempted (as Research Dean of a medical school) to induce a colleague to repeat his trick of signing false declarations to journals, and his admissions that he too failed to secure data from Procter and Gamble (relevant parts highlighted). My own more substantial evidence seems somewhat irrelevant to the "sifting" given this. In any event, I withdrew from **2005/3223** after 430 days of slug-like inaction.

While awaiting reply from Professor Catto (or substitute) please answer the following under the terms of the FOI Act 2000. **1)** What is the official interpretation of the words "**screening**" and "**sifting**" in terms of FTP concerns? **2)** What expectations does the GMC have of senior clinicians who place themselves in a position of responsibility over research governance?

Kind wishes



Dr Aubrey Blumsohn
Consultant in Laboratory Medicine
Sheffield Teaching Hospitals



Division of Clinical Sciences (North)
Academic Unit of Bone Metabolism

R Eastell, Professor of Bone Metabolism

Research Dean, School of Medicine & Biomedical Sciences

RE/GKH

Northern General Hospi

Herries R

Sheffield S5 7

Tel: (0114) 271 4

Fax: (0114) 261 4

Email: r.eastell@sheffield.a

Web: www.shef.ac.uk/

13th December 2004

Dr Aubrey Blumsohn
Senior Lecturer in Metabolic Bone Disease
Clinical Sciences Centre
Northern General Hospital
Sheffield S5 7AU


Dear Aubrey

Re: letter of 8th November 2004

Thank you for your letter about the manuscript I have been preparing with Professor Pierre Delmas and Dr Ian Barton. I note from your letter that you would like to be a co-author of this work. I also note that you disagree with the approach we have taken to data analysis. You will realise that when we submit the manuscript to a journal that you will need to sign an authorship agreement form stating that you are in full agreement with the work. If you wish to be a coauthor then you need to work towards a resolution of the issues we described in our letter. We have listened carefully to your concerns, and we feel that we have addressed all of these. We have now prepared several drafts of the manuscript and would like to submit this shortly. Please reassure us that you are prepared to work with us constructively on this manuscript in a timely way. We would like you to respond to this letter within the next month and if you still wish to be a coauthor then we will send you the manuscript for your comments. We would appreciate you giving us your comments in a clear and constructive fashion within a month of us sending you the manuscript.

continued. . .


- 2 -



You mention the issue of probity and from your previous e-mails I understand that your major concern is that you have not had access to the original data. I have checked with Aventis and with other pharmaceutical companies in the field of osteoporosis for their guidelines to publication. They state that they take the approach described in the PhRMA guidelines and that in these guidelines there is not access to the data (other than those from your centre) for investigators. I think that the approach we have taken for this manuscript of working closely with the statisticians to identify the best approach to analyse the data is an example of best practice, particularly the visit that Ian Barton paid you to go through the data analysis in detail and actually conduct the data analysis during the visit.

Please let us know whether you still wish to be co-author on this manuscript,

Yours sincerely



Richard Eastell
Professor of Bone Metabolism

6-7 Park Place
Leeds
LS1 2RU
www.rlb-law.com
Direct Dial +44 (0)113 261 5515

Tel +44 (0)113 234 1220
Fax +44 (0)113 234 1573
DX 14086 Leeds Park Square
info@rlb-law.com
kate.williams@rlb-law.com

COPY LETTER

RadcliffesLeBrasseur

Messrs McKay Law
Solicitors
41 St Paul's Street
LEEDS
LS1 2JG

9 June 2005

Our Ref: CJW2/MD/900100.8703

Your Ref: SM DO

L 250363 v1

Dear Sirs

Re: Our Clients - Professor R Eastell

We act for the Medical Protection Society on behalf of its member Professor Eastell. We have been passed a copy of your letter to Professor Eastell dated 25th May, asking for certain raw data underlying certain abstracts, which you identify.

As you say, your client has asked for this information before. But it is not information to which Professor Eastell has access. It belongs to the pharmaceutical companies. As your client knows, Professor Eastell has already requested the data from the Pharmaceutical companies. (Professor Eastell explained this in a letter to your client dated 13th December 2004, a copy of which is enclosed). Therefore Professor Eastell regrets that he is unable to help.

Yours faithfully,

RadcliffesLeBrasseur

COPY

